We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00976170
First Posted: September 14, 2009
Last Update Posted: October 3, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Chugai Pharmaceutical
September 9, 2009
September 14, 2009
October 3, 2014
September 2009
July 2013   (Final data collection date for primary outcome measure)
  • Toxicity evaluation in accordance with CTCAE v3.0 [ Time Frame: Continuous ]
  • Dose limiting toxicity and maximum tolerated dose [ Time Frame: Continuous ]
Same as current
Complete list of historical versions of study NCT00976170 on ClinicalTrials.gov Archive Site
  • RECIST criteria (version 1.0) for response evaluation by CT/MRI in target and non-target lesions of HCC [ Time Frame: every 2 months ]
  • Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib [ Time Frame: Continuous ]
Same as current
Not Provided
Not Provided
 
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
This is a Phase I open-label dose escalation study of GC33 in combination with Sorafenib in patients with advanced or metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics, and efficacy. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hepatocellular Carcinoma
  • Drug: GC33(RO5137382)
    IV administration at 6 escalating dose levels.
  • Drug: Sorafenib
    Oral administration at 400mg twice daily or 400mg once daily
Experimental: 1
Interventions:
  • Drug: GC33(RO5137382)
  • Drug: Sorafenib
Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017 Feb;79(2):421-429. doi: 10.1007/s00280-017-3241-9. Epub 2017 Jan 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
42
September 2014
July 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed written Institutional Review Board/Ethical Committee approved informed consent form.
  • Male or female ≥18 years old.
  • Life expectancy ≥3 months.
  • ECOG Performance Status of 0-1.
  • Histologically confirmed hepatocellular carcinoma.
  • Not a candidate for curative treatments.
  • Child-Pugh A
  • Hematological, Biochemical and Organ Function:

    • AST (SGOT): ≤5.0 × ULN,
    • ALT (SGPT): ≤5.0 × ULN,
    • Total Bilirubin: ≤1.5mg/dL,
    • Platelets: ≥100,000/μL,
    • Absolute Neutrophil Count: ≥1,500/μL,
    • Serum creatinine: ≤2.0 × ULN,
    • PT-INR: ≤2.0
  • Ability to provide a tumor tissue sample either by:

    • A formalin fixed paraffin embedded block sample within 12 months prior to informed consent for HCC diagnosis
    • Undergo a biopsy to confirm HCC diagnosis
  • Measurable disease.

Exclusion Criteria:

  • Child-Pugh B or C
  • Patient who have taken Sorafenib previously.
  • Difficulty or inability to swallow pills.
  • Pregnant or lactating women or women of child-bearing potential and men of childbearing potential not willing to use effective means of contraception.
  • Patients known to be positive for Human immunodeficiency virus infection.
  • Active infectious diseases requiring treatment except for hepatitis B and C.
  • Other malignancies within the last 5 years.
  • History of transplantation (organ, bone marrow transplantation, Peripheral blood stem cell transplantation, etc.).
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements..
  • Patients with known brain metastases or other central nervous system disease/disorders.
  • Uncontrolled hypertension defined as systolic blood pressure >150 mmhg or diastolic blood pressure >90 mmHg, despite optimal medical management.
  • Non-tumor related thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
  • Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 3, any other hemorrhage/bleeding event ≥ CTCAE Grade 4 within 4 weeks of first dose of study drug.
  • Serious non-healing wound, ulcer, or bone fracture.
  • Patients who received major surgery, local therapy for HCC, chemotherapy, radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4 weeks prior to Day 1(6 weeks for nitrosoureas, mitomycin, and bevacizumab; 1 week for tumor biopsy).
  • Patients who received the following treatments within 2 weeks prior to Day 1:

    • Anticoagulant or thrombolytic agents for therapeutic purposes,
    • Systemic anti-viral therapy for hepatitis C and Interferon therapy for hepatitis B,
    • Blood transfusion including all blood products
  • Known history of hypersensitivity to similar agents.
  • Patients receiving any medications or substances that are inducers of CYP3A4 are ineligible: rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital and dexamethasone.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan,   United States
 
 
NCT00976170
GC-002US
Not Provided
Not Provided
Not Provided
Chugai Pharmaceutical
Chugai Pharmaceutical
Hoffmann-La Roche
Not Provided
Chugai Pharmaceutical
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP